Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway

Virus Research

Volumn 208, Issue , 2015, Pages 7-12

  Wang, Hongwei ^a   Gao, Haili ^a   Duan, Shupeng ^a   Song, Xinwen ^a  

^a The Clinical Laboratory of the First Affiliated Hospital of Xinxiang Medical University   (China)

Author keywords

HCV replication; MiR 199a 5p; Overexpression; Pro survival pathway

Indexed keywords

BETA CATENIN; MICRORNA; MICRORNA 199A 5P; MITOGEN ACTIVATED PROTEIN KINASE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PROTEIN KINASE B; UNCLASSIFIED DRUG; MIRN199 MICRORNA, HUMAN;

ADULT; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS REPLICATION; CELL LINE; CELL PROLIFERATION; GENETICS; HEPACIVIRUS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS;

CELL LINE; CELL PROLIFERATION; DOWN-REGULATION; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; MICRORNAS; UP-REGULATION; VIRUS REPLICATION;

EID: 84938603370     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2015.05.002     Document Type: Article

References (35)

1. Baek J., Kang S., Min H. MicroRNA-targeting therapeutics for hepatitis C. Arch. Pharm. Res. 2014, 37:299-305.
2. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
3. Bataller R., Paik Y.-H., Lindquist J.N., Lemasters J.J., Brenner D.A. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004, 126:529-540.
4. Canini L., DebRoy S., Marino Z., Conway J.M., Crespo G., Navasa M., D'Amato M., Ferenci P., Cotler S.J., Forns X., Perelson A.S., Dahari H. Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antivir. Ther. 2015, 20:149-155.
5. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
6. Cool C.D., Voelkel N.F., Bull T. Viral infection and pulmonary hypertension: is there an association?. Expert. Rev. Respir. Med. 2011, 5:207-216.
7. Dai B.H., Geng L., Wang Y., Sui C.J., Xie F., Shen R.X., Shen W.F., Yang J.M. microRNA-199a-5p protects hepatocytes from bile acid-induced sustained endoplasmic reticulum stress. Cell Death Dis. 2013, 4:e604.
8. De Francesco R., Tomei L., Altamura S., Summa V., Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antivir. Res. 2003, 58:1-16.
9. Edamoto Y., Hara A., Biernat W., Terracciano L., Cathomas G., Riehle H.M., Matsuda M., Fujii H., Scoazec J.Y., Ohgaki H. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int. J. Cancer 2003, 106:334-341.
10. Fornari F., Milazzo M., Chieco P., Negrini M., Calin G.A., Grazi G.L., Pollutri D., Croce C.M., Bolondi L., Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010, 70:5184-5193.
11. Gabr S.A., Berika M.Y., Alghadir A.H. Apoptosis and clinical severity in patients with psoriasis and HCV infection. Indian J. Dermatol. 2014, 59:230-236.
12. Gu S., Chan W.Y. Flexible and versatile as a Chameleon-sophisticated functions of microRNA-199a. Int. J. Mol. Sci. 2012, 13:8449-8466.
13. Gupta P., Cairns M.J., Saksena N.K. Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol. J. 2014, 11:64.
14. Huang Y., Shen X.J., Zou Q., Wang S.P., Tang S.M., Zhang G.Z. Biological functions of microRNAs: a review. J. Physiol. Biochem. 2011, 67:129-139.
15. Huang Y., Staschke K., De Francesco R., Tan S.L. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?. Virology 2007, 364:1-9.
16. Kohli A., Shaffer A., Sherman A., Kottilil S. Treatment of hepatitis C: a systematic review. J. Am. Med. Assoc. 2014, 312:631-640.
17. Li G., Cai G., Li D., Yin W. MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma. Postgrad. Med. J. 2014, 90:106-112.
18. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
19. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
20. Liu J., Wang Y., Pan Q., Su Y., Zhang Z., Han J., Zhu X., Tang C., Hu D. Wnt/beta-catenin pathway forms a negative feedback loop during TGF-beta1 induced human normal skin fibroblast-to-myofibroblast transition. J. Dermatol. Sci. 2012, 65:38-49.
21. Machlin E.S., Sarnow P., Sagan S.M. Combating hepatitis C virus by targeting microRNA-122 using locked nucleic acids. Curr. Gene Ther. 2012, 12:301-306.
22. Mannova P., Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J. Virol. 2005, 79:8742-8749.
23. Mobus S., Yang D., Yuan Q., Ludtke T.H., Balakrishnan A., Sgodda M., Rani B., Kispert A., Arauzo-Bravo M.J., Vogel A., Manns M.P., Ott M., Cantz T., Sharma A.D. MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells. J. Hepatol. 2014, 62:101-110.
24. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5:453-463.
25. O'Boyle Ii D.R., Sun J.H., Nower P.T., Lemm J.A., Fridell R.A., Wang C., Romine J.L., Belema M., Nguyen V.N., Laurent D.R., Serrano-Wu M., Snyder L.B., Meanwell N.A., Langley D.R., Gao M. Characterizations of HCV NS5A replication complex inhibitors. Virology 2013, 444:343-354.
26. Parfieniuk A., Jaroszewicz J., Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J. Gastroenterol. 2007, 13:5673-5681.
27. Scheel T.K., Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013, 19:837-849.
28. Schmitz K.J., Wohlschlaeger J., Lang H., Sotiropoulos G.C., Malago M., Steveling K., Reis H., Cicinnati V.R., Schmid K.W., Baba H.A. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol. 2008, 48:83-90.
29. Shen Q., Cicinnati V.R., Zhang X., Iacob S., Weber F., Sotiropoulos G.C., Radtke A., Lu M., Paul A., Gerken G., Beckebaum S. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol. Cancer 2010, 9:227.
30. Shrivastava S., Mukherjee A., Ray R.B. Hepatitis C virus infection, microRNA and liver disease progression. World J. Hepatol. 2013, 5:479-486.
31. Shukla G.C., Singh J., Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol. Cell. Pharmacol. 2011, 3:83-92.
32. Thibault P.A., Wilson J.A. Targeting miRNAs to treat hepatitis C virus infections and liver pathology: inhibiting the virus and altering the host. Pharmacol. Res. 2013, 75:48-59.
33. Waldron P.R., Holodniy M. MicroRNA and hepatitis C virus-challenges in investigation and translation: a review of the literature. Diagn. Microbiol. Infect. Dis. 2014, 80:1-12.
34. Zhang G.L., Li Y.X., Zheng S.Q., Liu M., Li X., Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antivir. Res. 2010, 88:169-175.
35. Zhang Y., Wei W., Cheng N., Wang K., Li B., Jiang X., Sun S. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012, 56:1631-1640.